Innovus Pharmaceuticals Inc (INNV) 0.3900 $INNV
Innovus Pharma Signs License Agreement With Sothema Laboratories for Zestra(R) and Zestra Glide(R) in the Middle East (Excluding Lebanon and Israel), North Africa and West Africa
GlobeNewswire - Wed Sep 24, 5:15AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma"
www.innovuspharma.com (OTCBB:INNV) announced today it has entered into an exclusive license agreement with Sothema Laboratories, SARL, a Moroccan company (SOT.CSE) ("Sothema" under which Innovus Pharma granted to Sothema an exclusive license to market and sell Innovus Pharma's topical treatment for Female Sexual Desire Disorder ("FSDD" , Zestra(R) and its high viscosity water-based lubricant Zestra Glide(R) in the North African countries of Egypt, Morocco, Algeria, Tunisia and Libya, the Middle Eastern countries of Iraq, Jordan, Saudi Arabia and the United Arab Emirates (excluding Lebanon and Israel) and the West African countries of Benin, Burkina Faso, Cape Verde, Gambia, Ghana, Guinea, Guinea-Bissau, Ivory Coast, Liberia, Mali, Niger, Nigeria, Senegal, Sierra Leone and Togo (collectively the "Territory" . Under the agreement, Innovus will receive an upfront payment and is eligible to receive up to approximately $171.25 million U.S. dollars upon and subject to the achievement of sales milestones based on cumulative supplied units of the licensed products in the Territory plus a pre-negotiated transfer price per unit.
Innovus Pharma Signs License Agreement With Orimed Pharma for Zestra(R), EjectDelay(TM), Sensum+(TM) and Zestra Glide(R) in Canada
GlobeNewswire - Mon Sep 22, 5:15AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" www.innovuspharma.com (OTCBB:INNV) announced today it has entered into a license agreement with Orimed Pharma ("Orimed" , an affiliate of JAMP Pharma, under which Innovus Pharma granted to Orimed an exclusive license to market and sell Innovus Pharma's topical treatment for Female Sexual Desire Disorder("FSDD" , Zestra(R), its topical treatment for premature ejaculation, EjectDelay(TM), its product Sensum+(TM) (previously called CIRCUMSerum(TM)) to increase penile sensitivity and its high viscosity water based lubricant, Zestra Glide(R) in Canada. Under the agreement, Innovus will receive an upfront payment and is eligible to receive up to approximately $94.5 million Canadian dollars upon and subject to the achievement of sales milestones based on cumulative gross sales in Canada by Orimed plus certain double-digit tiered royalties based on Orimed's cumulative net sales in Canada.
Innovus Pharma to market and distribute Sensum+ in the UK through Tramorgan
M2 - Thu Sep 18, 6:12AM CDT
Pharmaceutical company Innovus Pharmaceuticals (Other OTC:INNV) reported on Thursday the grant of an exclusive marketing sales and distribution right to its topical consumer care product Sensum+ in the UK to UK based Tramorgan.
Innovus Pharma Signs Exclusive Marketing Sales and Distribution Agreement With Tramorgan Limited to Market and Distribute Sensum+(TM) in the United Kingdom
GlobeNewswire - Thu Sep 18, 5:15AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" www.innovuspharma.com (OTCQB:INNV) announced today that it has entered into an exclusive marketing and distribution agreement with Tramorgan Limited, a British company ("Tramorgan" under which Innovus Pharma has granted to Tramorgan an exclusive marketing sales and distribution right to market and sell Innovus Pharma's topical consumer care product to increase penile sensitivity, Sensum+(TM) in the United Kingdom ("UK" . The agreement has an initial term of December 31, 2016 and can be extended thereafter for a twenty-four month period if Tramorgan has reached certain aggregate sales milestones. Pursuant to the agreement, Innovus Pharma is eligible to receive (a) up to $44 million dollars in sales milestone payments based on Tramorgan's attainment of certain levels of cumulative gross sales amounts plus (b) fifty percent (50%) royalties based on Tramorgan's net sales after distribution costs in the UK. The product will be available in 10ml multi-dose dispenser and single use packets.
Innovus Pharmaceuticals signs non-exclusive sampling, marketing and distribution agreement for Zestra in the US
M2 - Tue Sep 09, 6:42AM CDT
Innovus Pharmaceuticals (Other OTC:INNV), a provider of sexual dysfunction products, revealed on Monday the launch of an non-exclusive sampling, marketing and distribution agreement for Zestra with Bulu Bo.
Innovus Pharmaceuticals, Inc. (OTCQB:INNV), Exclusive Interview for Interlinked's Investment News Channel
PRWeb - Mon Sep 08, 6:05AM CDT
Innovus Pharma was one of the presenting companies at the recent FSXinterlinked Investment Conference, held at the Four Seasons Hotel in Westlake Village, California.
Innovus Pharma Expands US Distribution by Signing a Non-Exclusive Sampling and Distribution Agreement With Bulu Box(R) for Zestra(R) in the US
GlobeNewswire - Mon Sep 08, 5:00AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" www.innovuspharma.com (OTCQB:INNV), announced today it has entered into an non-exclusive sampling, marketing and distribution agreement with Bulu Box(R) ("Bulu Box" under which Bulu Box will add Zestra(R) as part of its monthly box to all current subscribers. In addition, Bulu Box will sell Zestra(R) 3 packettes box through its E-commerce platform in the US.
Innovus Pharma to Present at the 2014 Aegis Healthcare Conference in Las Vegas, NV and the See Thru Equity Fall Microcap Investor Conference in New York
GlobeNewswire - Thu Sep 04, 5:00AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company) www.innovuspharma.com (OTCBB:INNV) today announced that Dr. Bassam Damaj, President & CEO of the Company is scheduled to present at the 2014 Aegis Healthcare Conference to be held September 10-13, 2014 at The Encore at Wynn Las Vegas. The Company's presentation will be on Friday, September 12th at 8:00 a.m. PDT.
Innovus Pharma to market and distribute Zestra for alternative markets through DanaLife ApS
M2 - Thu Aug 28, 6:56AM CDT
Pharmaceutical company Innovus Pharmaceuticals (Other OTC:INNV) Thursday executed an exclusive marketing and distribution agreement to grant the worldwide distribution right (excluding Canada) to market and sell its topical consumer care product Zestra in the alternative markets that excludes all medical and mainstream sales channels.
Innovus Pharma Signs Exclusive Marketing and Distribution Agreement With DanaLife ApS to Market and Distribute Zestra(R) for Alternative Markets
GlobeNewswire - Thu Aug 28, 5:21AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" www.innovuspharma.com (OTCQB:INNV) announced today it has entered into an exclusive marketing and distribution agreement with DanaLife ApS based in Denmark ("DanaLife" under which Innovus Pharma has granted to DanaLife an exclusive 18 month worldwide distribution right ( excluding Canada) , to market and sell Innovus Pharma's topical consumer care product to increase Female Sexual Arousal and Desire and Satisfaction, Zestra(R) for the alternative markets which excludes all medical and mainstream sales channels. The Company is in the process of negotiating commercial agreements with Pharmaceutical companies to promote the product in the medical and mainstream channels. Under the agreement the initial minimum orders are expected to be two hundred and fifty thousand US dollars. The terms of the agreement can be extended automatically by another 18 months if DanaLife meets certain minimum sales numbers.
Innovus Announces Formation of a Global Clinical Advisory Board to Support the Growth of Its Product Zestra(R)
GlobeNewswire - Thu Aug 21, 5:25AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or "Company" (www.innovuspharma.com) (OTCQB:INNV), announced today the formation of a Clinical Advisory Board made up of top key opinion leaders in the fields of gynecology and sexual health to support the continued growth of its Zestra product. The Clinical Advisory Board will work closely with the Innovus Pharma management team in addressing health authorities, outlining clinical protocols and surveys, as well as presenting Innovus Pharma at academic and industry meetings for its marketed and currently in-development products.
Innovus Pharma and Consortia Health Initiate a Nationwide Marketing and Sales Campaign to U.S. Gynecologists for Zestra(R), Clinically Proven for the Enhancement of Female Arousal Desire and Satisfaction
GlobeNewswire - Fri Aug 15, 5:00AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company) www.innovuspharma.com (OTCBB:INNV) a leader in over-the-counter ("OTC" and consumer care products for men and women's sexual dysfunction and health products announced today that its U.S. sales and marketing partner, Consortia Health, began recently the detailing of its Zestra(R) product clinically proven to enhance arousal, desire and satisfaction in women to gynecologists in 13 states. Consortia's 25 member sales force is composed of sales representatives and nurse practitioners. The sales force currently covers over 50% of the US population in the following U.S. states: Pennsylvania, Michigan, Nevada, Texas, Florida, Louisiana, Georgia, New York, New Jersey, Colorado, Washington, Utah, California, North Carolina and Arizona.
Innovus Pharma awarded higher line of credit of USD1.5m from CEO
M2 - Thu Aug 07, 7:03AM CDT
Sexual dysfunction company Innovus Pharmaceuticals (Other OTC:INNV) reported on Wednesday a rise in its line of credit with its president and CEO, Dr Bassam Damaj, to USD1.5m.
Innovus Pharma Secures Additional Funding by Increasing Its Line of Credit With Its Chief Executive Officer to $1.5M, Provides Quarter Update and Timing of Its 10-Q Filing
GlobeNewswire - Wed Aug 06, 5:01AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company" www.innovuspharma.com (OTCQB:INNV) today announced that the Company increased its Line of Credit with Dr. Bassam Damaj, its President & CEO to a total of $1.5M. This added funding combined with the revenues from sales of commercial products both in the US and Canada, as well as from the new international partnerships the Company expects to announce this year, the Company believes, will provide a cash runway until Q2 2015. "My strong belief in the success of the Company and its commercial pipeline makes my commitment to Innovus unwavering," said Dr. Damaj, President & Chief Executive Officer of the Company.
Innovus Pharma to Present at the FSXinterlinked Financial Investment Conference in Westlake Village, CA
GlobeNewswire - Mon Jul 28, 1:32PM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company) www.innovuspharma.com (OTCBB:INNV) today announced that Dr. Bassam Damaj, President & CEO of the Company will present to an audience of principals and key decision makers of broker/dealers and financial firms at the FSXinterlinked Financial Investment Conference to be held at the Four Season Westlake Village, California from July 30-August 2, 2014. The presentation will take place on Thursday, July 31, 2014 at 1:57pm.
Innovus Pharma Provides Corporate Update
ACCESSWIRE - Wed Jun 25, 5:29AM CDT
San Diego, CA / ACCESSWIRE / June 25, 2014 / Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company" (OTCBB: INNV) (http://www.innovuspharma.com/) announced today a corporate mid-year update covering Company activities, expected near-term events and comments on recent market conditions, as follows:
Personal Accident and Health Insurance in Greece, Key Trends and Opportunities to 2017
M2 - Wed Feb 26, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/bjj4j7/personal_accident) has announced the addition of the "Personal Accident and Health Insurance in Greece, Key Trends and Opportunities to 2017" report to their offering. The Greek personal accident and health insurance segment accounted for the lowest share of premiums in the overall insurance industry in 2012. Demand for healthcare services and private health insurance increased during the review period (2008-2012), due to the inadequate service provided by public healthcare institutions and increasing per capita healthcare expenditure. Travel insurance accounted for the largest share of the segment. Growth in the category was supported by the introduction of low-cost airlines which increased the number of outbound tourists. Over the forecast period (2012-2017), the growth of the personal accident and health segment is expected to be driven by the travel and health insurance categories. Overall, the value of the Greek personal accident and health segment is expected to increase at a forecast-period compound annual growth rate (CAGR) of 5.5%. Key Topics Covered 1 Executive Summary 2 Introduction 3 Greek Insurance Industry Attractiveness 4 Personal Accident and Health Insurance Segment Outlook 5 Analysis by Distribution Channels 6 Porter's Five Forces Analysis - Greek Personal Accident and Health Insurance 7 Reinsurance Growth Dynamics and Challenges 8 Governance, Risk and Compliance 9 Competitive Landscape and Strategic Insights 10 Business Environment and Country Risk 11 Appendix Companies Mentioned - Eurolife - ING Greek Life Insurance - Metlife Alico For more information visit http://www.researchandmarkets.com/research/bj...l_accident About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Innovus Pharma reports market launch of EjectDelay in the US
M2 - Mon Feb 24, 7:02AM CST
Pharmaceuticals company Innovus Pharmaceuticals (Other OTC:INNV) disclosed on Friday the market availability of its over the counter (OTC) benzocaine-based topical premature ejaculation treatment, EjectDelay, in the US.
Innovus Pharma Announces Availability of EjectDelay(TM) for Premature Ejaculation in the United States
GlobeNewswire - Fri Feb 21, 5:00AM CST
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company" www.innovuspharma.com (OTCBB:INNV) today announced the availability of its over the counter ("OTC" benzocaine-based topical premature ejaculation treatment EjectDelay(TM) in the United States ("U.S." .
Innovus Pharma to Exhibit Zestra(R) its Clinically Proven Product for Female Sexual Arousal and Desire at the International Society for the Study of Women's Sexual Health 2014 Annual Meeting in San Diego
GlobeNewswire - Thu Feb 20, 9:00AM CST
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company" www.innovuspharma.com (OTC BB:INNV) today announced that it will exhibit Zestra(R), its topical over the counter ("OTC" product for female sexual arousal and desire at the 2014 Annual International Society for the Study of Women's Sexual Health Meeting in San Diego from February 20-22, 2014.
Innovus Pharma Signs License Agreement With Sothema Laboratories for Zestra(R) and Zestra Glide(R) in the Middle East (Excluding Lebanon and Israel), North Africa and West Africa
GlobeNewswire - Wed Sep 24, 5:15AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma"
www.innovuspharma.com (OTCBB:INNV) announced today it has entered into an exclusive license agreement with Sothema Laboratories, SARL, a Moroccan company (SOT.CSE) ("Sothema" under which Innovus Pharma granted to Sothema an exclusive license to market and sell Innovus Pharma's topical treatment for Female Sexual Desire Disorder ("FSDD" , Zestra(R) and its high viscosity water-based lubricant Zestra Glide(R) in the North African countries of Egypt, Morocco, Algeria, Tunisia and Libya, the Middle Eastern countries of Iraq, Jordan, Saudi Arabia and the United Arab Emirates (excluding Lebanon and Israel) and the West African countries of Benin, Burkina Faso, Cape Verde, Gambia, Ghana, Guinea, Guinea-Bissau, Ivory Coast, Liberia, Mali, Niger, Nigeria, Senegal, Sierra Leone and Togo (collectively the "Territory" . Under the agreement, Innovus will receive an upfront payment and is eligible to receive up to approximately $171.25 million U.S. dollars upon and subject to the achievement of sales milestones based on cumulative supplied units of the licensed products in the Territory plus a pre-negotiated transfer price per unit. Innovus Pharma Signs License Agreement With Orimed Pharma for Zestra(R), EjectDelay(TM), Sensum+(TM) and Zestra Glide(R) in Canada
GlobeNewswire - Mon Sep 22, 5:15AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma"
www.innovuspharma.com (OTCBB:INNV) announced today it has entered into a license agreement with Orimed Pharma ("Orimed" , an affiliate of JAMP Pharma, under which Innovus Pharma granted to Orimed an exclusive license to market and sell Innovus Pharma's topical treatment for Female Sexual Desire Disorder("FSDD" , Zestra(R), its topical treatment for premature ejaculation, EjectDelay(TM), its product Sensum+(TM) (previously called CIRCUMSerum(TM)) to increase penile sensitivity and its high viscosity water based lubricant, Zestra Glide(R) in Canada. Under the agreement, Innovus will receive an upfront payment and is eligible to receive up to approximately $94.5 million Canadian dollars upon and subject to the achievement of sales milestones based on cumulative gross sales in Canada by Orimed plus certain double-digit tiered royalties based on Orimed's cumulative net sales in Canada. Innovus Pharma to market and distribute Sensum+ in the UK through Tramorgan
M2 - Thu Sep 18, 6:12AM CDT
Pharmaceutical company Innovus Pharmaceuticals (Other OTC:INNV) reported on Thursday the grant of an exclusive marketing sales and distribution right to its topical consumer care product Sensum+ in the UK to UK based Tramorgan.
Innovus Pharma Signs Exclusive Marketing Sales and Distribution Agreement With Tramorgan Limited to Market and Distribute Sensum+(TM) in the United Kingdom
GlobeNewswire - Thu Sep 18, 5:15AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma"
www.innovuspharma.com (OTCQB:INNV) announced today that it has entered into an exclusive marketing and distribution agreement with Tramorgan Limited, a British company ("Tramorgan" under which Innovus Pharma has granted to Tramorgan an exclusive marketing sales and distribution right to market and sell Innovus Pharma's topical consumer care product to increase penile sensitivity, Sensum+(TM) in the United Kingdom ("UK" . The agreement has an initial term of December 31, 2016 and can be extended thereafter for a twenty-four month period if Tramorgan has reached certain aggregate sales milestones. Pursuant to the agreement, Innovus Pharma is eligible to receive (a) up to $44 million dollars in sales milestone payments based on Tramorgan's attainment of certain levels of cumulative gross sales amounts plus (b) fifty percent (50%) royalties based on Tramorgan's net sales after distribution costs in the UK. The product will be available in 10ml multi-dose dispenser and single use packets. Innovus Pharmaceuticals signs non-exclusive sampling, marketing and distribution agreement for Zestra in the US
M2 - Tue Sep 09, 6:42AM CDT
Innovus Pharmaceuticals (Other OTC:INNV), a provider of sexual dysfunction products, revealed on Monday the launch of an non-exclusive sampling, marketing and distribution agreement for Zestra with Bulu Bo.
Innovus Pharmaceuticals, Inc. (OTCQB:INNV), Exclusive Interview for Interlinked's Investment News Channel
PRWeb - Mon Sep 08, 6:05AM CDT
Innovus Pharma was one of the presenting companies at the recent FSXinterlinked Investment Conference, held at the Four Seasons Hotel in Westlake Village, California.
Innovus Pharma Expands US Distribution by Signing a Non-Exclusive Sampling and Distribution Agreement With Bulu Box(R) for Zestra(R) in the US
GlobeNewswire - Mon Sep 08, 5:00AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma"
www.innovuspharma.com (OTCQB:INNV), announced today it has entered into an non-exclusive sampling, marketing and distribution agreement with Bulu Box(R) ("Bulu Box" under which Bulu Box will add Zestra(R) as part of its monthly box to all current subscribers. In addition, Bulu Box will sell Zestra(R) 3 packettes box through its E-commerce platform in the US. Innovus Pharma to Present at the 2014 Aegis Healthcare Conference in Las Vegas, NV and the See Thru Equity Fall Microcap Investor Conference in New York
GlobeNewswire - Thu Sep 04, 5:00AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company) www.innovuspharma.com (OTCBB:INNV) today announced that Dr. Bassam Damaj, President & CEO of the Company is scheduled to present at the 2014 Aegis Healthcare Conference to be held September 10-13, 2014 at The Encore at Wynn Las Vegas. The Company's presentation will be on Friday, September 12th at 8:00 a.m. PDT.
Innovus Pharma to market and distribute Zestra for alternative markets through DanaLife ApS
M2 - Thu Aug 28, 6:56AM CDT
Pharmaceutical company Innovus Pharmaceuticals (Other OTC:INNV) Thursday executed an exclusive marketing and distribution agreement to grant the worldwide distribution right (excluding Canada) to market and sell its topical consumer care product Zestra in the alternative markets that excludes all medical and mainstream sales channels.
Innovus Pharma Signs Exclusive Marketing and Distribution Agreement With DanaLife ApS to Market and Distribute Zestra(R) for Alternative Markets
GlobeNewswire - Thu Aug 28, 5:21AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma"
www.innovuspharma.com (OTCQB:INNV) announced today it has entered into an exclusive marketing and distribution agreement with DanaLife ApS based in Denmark ("DanaLife" under which Innovus Pharma has granted to DanaLife an exclusive 18 month worldwide distribution right ( excluding Canada) , to market and sell Innovus Pharma's topical consumer care product to increase Female Sexual Arousal and Desire and Satisfaction, Zestra(R) for the alternative markets which excludes all medical and mainstream sales channels. The Company is in the process of negotiating commercial agreements with Pharmaceutical companies to promote the product in the medical and mainstream channels. Under the agreement the initial minimum orders are expected to be two hundred and fifty thousand US dollars. The terms of the agreement can be extended automatically by another 18 months if DanaLife meets certain minimum sales numbers. Innovus Announces Formation of a Global Clinical Advisory Board to Support the Growth of Its Product Zestra(R)
GlobeNewswire - Thu Aug 21, 5:25AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or "Company"
(www.innovuspharma.com) (OTCQB:INNV), announced today the formation of a Clinical Advisory Board made up of top key opinion leaders in the fields of gynecology and sexual health to support the continued growth of its Zestra product. The Clinical Advisory Board will work closely with the Innovus Pharma management team in addressing health authorities, outlining clinical protocols and surveys, as well as presenting Innovus Pharma at academic and industry meetings for its marketed and currently in-development products. Innovus Pharma and Consortia Health Initiate a Nationwide Marketing and Sales Campaign to U.S. Gynecologists for Zestra(R), Clinically Proven for the Enhancement of Female Arousal Desire and Satisfaction
GlobeNewswire - Fri Aug 15, 5:00AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company) www.innovuspharma.com (OTCBB:INNV) a leader in over-the-counter ("OTC"
and consumer care products for men and women's sexual dysfunction and health products announced today that its U.S. sales and marketing partner, Consortia Health, began recently the detailing of its Zestra(R) product clinically proven to enhance arousal, desire and satisfaction in women to gynecologists in 13 states. Consortia's 25 member sales force is composed of sales representatives and nurse practitioners. The sales force currently covers over 50% of the US population in the following U.S. states: Pennsylvania, Michigan, Nevada, Texas, Florida, Louisiana, Georgia, New York, New Jersey, Colorado, Washington, Utah, California, North Carolina and Arizona. Innovus Pharma awarded higher line of credit of USD1.5m from CEO
M2 - Thu Aug 07, 7:03AM CDT
Sexual dysfunction company Innovus Pharmaceuticals (Other OTC:INNV) reported on Wednesday a rise in its line of credit with its president and CEO, Dr Bassam Damaj, to USD1.5m.
Innovus Pharma Secures Additional Funding by Increasing Its Line of Credit With Its Chief Executive Officer to $1.5M, Provides Quarter Update and Timing of Its 10-Q Filing
GlobeNewswire - Wed Aug 06, 5:01AM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company"
www.innovuspharma.com (OTCQB:INNV) today announced that the Company increased its Line of Credit with Dr. Bassam Damaj, its President & CEO to a total of $1.5M. This added funding combined with the revenues from sales of commercial products both in the US and Canada, as well as from the new international partnerships the Company expects to announce this year, the Company believes, will provide a cash runway until Q2 2015. "My strong belief in the success of the Company and its commercial pipeline makes my commitment to Innovus unwavering," said Dr. Damaj, President & Chief Executive Officer of the Company. Innovus Pharma to Present at the FSXinterlinked Financial Investment Conference in Westlake Village, CA
GlobeNewswire - Mon Jul 28, 1:32PM CDT
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company) www.innovuspharma.com (OTCBB:INNV) today announced that Dr. Bassam Damaj, President & CEO of the Company will present to an audience of principals and key decision makers of broker/dealers and financial firms at the FSXinterlinked Financial Investment Conference to be held at the Four Season Westlake Village, California from July 30-August 2, 2014. The presentation will take place on Thursday, July 31, 2014 at 1:57pm.
Innovus Pharma Provides Corporate Update
ACCESSWIRE - Wed Jun 25, 5:29AM CDT
San Diego, CA / ACCESSWIRE / June 25, 2014 / Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the "Company"
(OTCBB: INNV) (http://www.innovuspharma.com/) announced today a corporate mid-year update covering Company activities, expected near-term events and comments on recent market conditions, as follows: Personal Accident and Health Insurance in Greece, Key Trends and Opportunities to 2017
M2 - Wed Feb 26, 4:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/bjj4j7/personal_accident) has announced the addition of the "Personal Accident and Health Insurance in Greece, Key Trends and Opportunities to 2017" report to their offering. The Greek personal accident and health insurance segment accounted for the lowest share of premiums in the overall insurance industry in 2012. Demand for healthcare services and private health insurance increased during the review period (2008-2012), due to the inadequate service provided by public healthcare institutions and increasing per capita healthcare expenditure. Travel insurance accounted for the largest share of the segment. Growth in the category was supported by the introduction of low-cost airlines which increased the number of outbound tourists. Over the forecast period (2012-2017), the growth of the personal accident and health segment is expected to be driven by the travel and health insurance categories. Overall, the value of the Greek personal accident and health segment is expected to increase at a forecast-period compound annual growth rate (CAGR) of 5.5%. Key Topics Covered 1 Executive Summary 2 Introduction 3 Greek Insurance Industry Attractiveness 4 Personal Accident and Health Insurance Segment Outlook 5 Analysis by Distribution Channels 6 Porter's Five Forces Analysis - Greek Personal Accident and Health Insurance 7 Reinsurance Growth Dynamics and Challenges 8 Governance, Risk and Compliance 9 Competitive Landscape and Strategic Insights 10 Business Environment and Country Risk 11 Appendix Companies Mentioned - Eurolife - ING Greek Life Insurance - Metlife Alico For more information visit http://www.researchandmarkets.com/research/bj...l_accident About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Innovus Pharma reports market launch of EjectDelay in the US
M2 - Mon Feb 24, 7:02AM CST
Pharmaceuticals company Innovus Pharmaceuticals (Other OTC:INNV) disclosed on Friday the market availability of its over the counter (OTC) benzocaine-based topical premature ejaculation treatment, EjectDelay, in the US.
Innovus Pharma Announces Availability of EjectDelay(TM) for Premature Ejaculation in the United States
GlobeNewswire - Fri Feb 21, 5:00AM CST
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company"
www.innovuspharma.com (OTCBB:INNV) today announced the availability of its over the counter ("OTC" benzocaine-based topical premature ejaculation treatment EjectDelay(TM) in the United States ("U.S." . Innovus Pharma to Exhibit Zestra(R) its Clinically Proven Product for Female Sexual Arousal and Desire at the International Society for the Study of Women's Sexual Health 2014 Annual Meeting in San Diego
GlobeNewswire - Thu Feb 20, 9:00AM CST
Innovus Pharmaceuticals, Inc., ("Innovus Pharma" or the "Company"
www.innovuspharma.com (OTC BB:INNV) today announced that it will exhibit Zestra(R), its topical over the counter ("OTC" product for female sexual arousal and desire at the 2014 Annual International Society for the Study of Women's Sexual Health Meeting in San Diego from February 20-22, 2014. 
